These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9332464)

  • 21. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
    Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
    Chen G; Zeller WJ; Todorov DK
    Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y
    Cancer Chemother Pharmacol; 1996; 37(6):525-30. PubMed ID: 8612305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
    Lee JW; Park JK; Lee SH; Kim SY; Cho YB; Kuh HJ
    Anticancer Drugs; 2006 Apr; 17(4):377-84. PubMed ID: 16549994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
    Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.
    Lenzi R; Frost P; Abbruzzese JL
    Anticancer Res; 1994; 14(1A):247-51. PubMed ID: 7513143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
    Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
    Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
    Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
    Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.
    Yunos NM; Beale P; Yu JQ; Huq F
    Anticancer Res; 2011 Apr; 31(4):1131-40. PubMed ID: 21508356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex.
    Ragazzi E; D'Ancona S; Berti E; Carrara M
    Anticancer Res; 2002; 22(5):2783-8. PubMed ID: 12529997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate.
    Bodo J; Chovancova J; Hunakova L; Sedlak J
    Neoplasma; 2005; 52(6):510-6. PubMed ID: 16284698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
    Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
    Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
    Chau Q; Stewart DJ
    Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Apoptosis induced by cisplatin and verapamil or SDZ PSC 833 in human ovarian cell lines].
    Liao M; Chen H; Shui H
    Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):101-4. PubMed ID: 11809110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G; Zeller WJ
    Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo.
    Liu Y; Wang LL; Deng Y
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Mar; 23(3):242-4. PubMed ID: 12651241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study on curcumin-induced apoptosis in ovarian cancer resistant cell lines COC1/DDP].
    Lin L; Wang P; Zhao XL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 May; 43(3):335-9. PubMed ID: 22812232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.